Congenital CMV in Australia: Reported Cases Are a Small Fraction of Estimated Burden — Implications for Screening, Treatment, and Public Health
Posted inInfectious Diseases news Pediatrics

Congenital CMV in Australia: Reported Cases Are a Small Fraction of Estimated Burden — Implications for Screening, Treatment, and Public Health

National APSU surveillance (1999–2024) found 479 definite congenital CMV cases and dramatic under-ascertainment versus expected prevalence; symptomatic infants increasingly receive antivirals. Expanded surveillance, newborn screening, and clear treatment pathways are needed.
Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial
Posted inClinical Updates Infectious Diseases news Specialties

Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial

The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanced responses in patients with lower baseline HBsAg levels.